Virtual Library
Start Your Search
Ito Hitoshi
Author of
-
+
P2.14 - Radiotherapy (ID 715)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.14-007 - Histological Difference in Outcomes of Definitive Chemoradiotherapy for non-small cell Lung Cancer (ID 8921)
09:30 - 09:30 | Presenting Author(s): Ito Hitoshi
- Abstract
Background:
[Background] Chemoradiotherapy is the standard treatment for locally advanced non-small cell lung cancer. Histological difference has not been taken into account in the chemoradiotherapy unlike in chemotherapy for metastatic disease. The purpose of this study is to evaluate the results and relapse pattern difference between squamous cell carcinoma (Sq) and adenocarcinoma (Ad) histology.
Method:
[Methods] We retrospectively analyzed the outcomes and relapse pattern in patients who received definitive chemoradiotherapy for locally advanced non-small cell lung cancer in our institute between 2003 and 2012
Result:
[Results] There were 74 Sq patients and 36 Ad patients. Sq patients had more advanced T Stage, and less female ratio. Other factors were well balanced. Median follow-up time in all patients and surviving patients were 21.3 and 79.6 month, respectively. Median survival time was not significantly different between Sq and Ad patients (P=0.61; 20.8 and 26.7 month, respectively). Relapse pattern was different between the two histologies (P=0.0149). Locoregional, distant, and simultaneous relapse of locoregional and distant sites were observed in 32 (55.2 %), 23 (39.8 %) and 3 (5.2 %) for Sq patients; and 7(22.6 %), 20(64.5 %) and 4(12.9 %) for Ad patients, respectively. The time from relapse to death in Sq patients were shorter than Ad patients (median, 8.9 months and 14.9 months; P=0.046). Numbers of patients surviving without any relapse for 5 years or more were 9 (12.2 %) in Sq and 1 (2.8 %) in Ad. Figure 1
Conclusion:
[Conclusion] More than 10% of Sq patients could achieve relapse-free survival longer than 5 years. However, in relapsed patients, prognosis was poorer in Sq patients compared to Ad patients. Dominant pattern of relapse was locoregional in the Sq patients. More aggressive local treatment such as combination with surgery or dose escalation of radiotherapy may improve survival in Sq patients.
